<DOC>
	<DOCNO>NCT01079182</DOCNO>
	<brief_summary>The research question explore study whether effectiveness safety adalimumab participant ankylose spondylitis maintain long-term therapy routine clinical practice Germany .</brief_summary>
	<brief_title>Basic Documentation Adalimumab ( Humira ) Patients With Ankylosing Spondylitis ( AS )</brief_title>
	<detailed_description>This postmarketing observational study ( PMOS ) participant insufficiently control , moderate severe , active AS eligible adalimumab therapy . Participants start treatment adalimumab normal clinical setting Germany . Enrolled participant follow adalimumab therapy . Participants assess regular clinic visit 24 month 359 clinician ( rheumatologists/orthopedists/general practitioners/internist ) participate study . Since observational trial , doctor follow stated age limitation participant age 18 enrol .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Participants active , AS least 4 week ( BASDAI great equal 4 ) . 2 . Participants fail treatment two nonsteroidal antiinflammatory drug ( NSAIDs ) . 3 . No contraindication antitumor necrosis factor ( TNF ) therapy . 1 . Participants meet listed inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Daily practice</keyword>
	<keyword>Humira</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Ankylosing spondylitis</keyword>
</DOC>